Baseline patient characteristics
| Characteristic . | Number of patients . |
|---|---|
| Total patients, n | 17 |
| Median age, y (range) | 62 (27-72) |
| Sex, n (%) | |
| Male | 9 (53) |
| Female | 8 (47) |
| Diagnosis, n | |
| ALL | 2 |
| AML | 3 |
| CML | 1 |
| HL | 3 |
| MDS | 2 |
| Myelofibrosis | 1 |
| NHL | 5 |
| Stem cell donor, n (%) | |
| HLA-matched sibling | 7 (41) |
| HLA-matched unrelated | 9 (53) |
| HLA-mismatched unrelated | 1 (6) |
| Stem cell source, n (%) | |
| Peripheral blood | 16 (94) |
| Bone marrow | 1 (6) |
| Conditioning regimen intensity, n (%) | |
| NMA/RIC | 10 (59) |
| Myeloablative | 7 (41) |
| cGVHD presentation, n (%) | |
| De novo | 15 (88) |
| Progressive | 2 (12) |
| NIH cGVHD severity, n (%) | |
| Mild | 1 (6) |
| Moderate | 6 (35) |
| Severe | 10 (59) |
| End-organ involvement, n (%) | |
| Skin | 16 (94) |
| Musculoskeletal | 16 (94) |
| Ocular | 9 (53) |
| Oral | 9 (53) |
| Urogenital | 6 (35) |
| Lung | 3 (18) |
| Gastrointestinal | 2 (12) |
| Liver alone | 2 (12) |
| Previous or concurrent systemic cGVHD therapies, n (%) | |
| Corticosteroids | 16 (94) |
| Rituximab | 7 (41) |
| Extracorporeal photopheresis | 6 (35) |
| Mycophenolate mofetil | 4 (24) |
| Tacrolimus | 4 (24) |
| Imatinib | 3 (18) |
| Brentuximab vedotin | 2 (12) |
| Interleukin-2 | 2 (12) |
| Sirolimus | 2 (12) |
| Median concurrent systemic cGVHD therapies at study enrollment, n (range) | 1 (0-3) |
| Concurrent systemic cGVHD therapies at study enrollment, n (%) | |
| Corticosteroids | 15 (88) |
| Mycophenolate mofetil | 4 (24) |
| Tacrolimus | 3 (18) |
| Sirolimus | 2 (12) |
| Median time from HCT to enrollment, months (range) | 40 (13-121) |
| Median time from cGVHD diagnosis to enrollment, months (range) | 31 (1-101) |
| Characteristic . | Number of patients . |
|---|---|
| Total patients, n | 17 |
| Median age, y (range) | 62 (27-72) |
| Sex, n (%) | |
| Male | 9 (53) |
| Female | 8 (47) |
| Diagnosis, n | |
| ALL | 2 |
| AML | 3 |
| CML | 1 |
| HL | 3 |
| MDS | 2 |
| Myelofibrosis | 1 |
| NHL | 5 |
| Stem cell donor, n (%) | |
| HLA-matched sibling | 7 (41) |
| HLA-matched unrelated | 9 (53) |
| HLA-mismatched unrelated | 1 (6) |
| Stem cell source, n (%) | |
| Peripheral blood | 16 (94) |
| Bone marrow | 1 (6) |
| Conditioning regimen intensity, n (%) | |
| NMA/RIC | 10 (59) |
| Myeloablative | 7 (41) |
| cGVHD presentation, n (%) | |
| De novo | 15 (88) |
| Progressive | 2 (12) |
| NIH cGVHD severity, n (%) | |
| Mild | 1 (6) |
| Moderate | 6 (35) |
| Severe | 10 (59) |
| End-organ involvement, n (%) | |
| Skin | 16 (94) |
| Musculoskeletal | 16 (94) |
| Ocular | 9 (53) |
| Oral | 9 (53) |
| Urogenital | 6 (35) |
| Lung | 3 (18) |
| Gastrointestinal | 2 (12) |
| Liver alone | 2 (12) |
| Previous or concurrent systemic cGVHD therapies, n (%) | |
| Corticosteroids | 16 (94) |
| Rituximab | 7 (41) |
| Extracorporeal photopheresis | 6 (35) |
| Mycophenolate mofetil | 4 (24) |
| Tacrolimus | 4 (24) |
| Imatinib | 3 (18) |
| Brentuximab vedotin | 2 (12) |
| Interleukin-2 | 2 (12) |
| Sirolimus | 2 (12) |
| Median concurrent systemic cGVHD therapies at study enrollment, n (range) | 1 (0-3) |
| Concurrent systemic cGVHD therapies at study enrollment, n (%) | |
| Corticosteroids | 15 (88) |
| Mycophenolate mofetil | 4 (24) |
| Tacrolimus | 3 (18) |
| Sirolimus | 2 (12) |
| Median time from HCT to enrollment, months (range) | 40 (13-121) |
| Median time from cGVHD diagnosis to enrollment, months (range) | 31 (1-101) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; cGVHD, chronic graft-versus-host disease; CML, chronic myeloid leukemia; HCT, hematopoietic cell transplantation; HL, Hodgkin lymphoma; HLA, human leukocyte antigen; NIH, National Institutes of Health; NMA, nonmyeloablative; RIC, reduced-intensity conditioning.